CGT Global Supports Renown Health in Advancing Breast Cancer Treatment in Nevada
RENO, Nev.--(BUSINESS WIRE)--CGT Global, a leader in cell and gene therapy access, is proud to announce their support for the Conrad Breast Center at Renown South Meadows Medical Center in Reno, Nevada. As part of CGT's contribution, the Center's Pharmacy Office will carry the 'CGT Global' name.
The financial contribution, made on behalf of CGT Global, our clients, and industry partners, reflects our mission to expand access to life-changing treatments. We are honored to support Renown Health's vision and help bring next-generation care to Nevada.
'Our support for Renown Health reflects CGT Global's broader vision to bring cutting-edge therapies from the lab bench to the bedside,' said Cate Spears, CEO & Founder of CGT Global. 'We believe scientific breakthroughs must translate into real-world impact. We love that the new breast cancer center will provide more fully integrated and multidisciplinary access to treatment across the region.'
The Conrad Breast Center will offer comprehensive services such as imaging, counseling for patients with increased risk for developing cancer , breast surgical oncology, medical oncology, radiation oncology, infusion therapy, evidence-based wellness medicine, and clinical research.
The Center opened last week, and promises world-class, patient-centered care. Renown Health's Pennington Cancer Institute has been recognized among the top 100 cancer programs in the US by Becker's Hospital Review.
CGT Global will continue to support organizations with a shared commitment to delivering cutting-edge therapies to local communities. Our support reflects our ongoing mission to enable emerging treatments like cell and gene therapy—powerful tools in the long-term fight against cancer. We believe that strong partnerships will help lead a new era of personalized medicine—grounded in science, community, and care.
About CGT Global
CGT Global is a biotechnology company advancing access to cell and gene therapies. With a national network of clinical sites and laboratories, CGT Global delivers high-quality biospecimens, GMP-compliant manufacturing, and end-to-end support to accelerate therapeutic development. Headquartered in Folsom, CA, CGT Global partners with top pharmaceutical companies, CROs, and hospitals. Learn more at www.cgt.global.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
AM Best Affirms Credit Ratings of Qatar Islamic Insurance Group Q.P.S.C.
LONDON--(BUSINESS WIRE)-- AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of 'a-' (Excellent) of Qatar Islamic Insurance Group Q.P.S.C. (QIIG) (Qatar). The outlook of these Credit Ratings (ratings) is stable. The ratings reflect QIIG's balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, limited business profile and appropriate enterprise risk management. QIIG is a takaful insurer and operates through a hybrid model, whereby the shareholders' fund charges the policyholders' fund (PHF) a Wakala fee based on gross written contributions (GWC) and a Mudarabah fee based on investment income. QIIG's balance sheet strength is underpinned by its risk-adjusted capitalisation at the strongest level, as measured by Best's Capital Adequacy Ratio (BCAR). AM Best assesses the company's risk-adjusted capitalisation on a combined basis, including its policyholders' and shareholders' funds, due to the strength of domestic regulation and requirement that the shareholders' fund would have to support the PHF were it to fall into deficit. Other positive balance sheet factors include the company's track record of internal capital generation through the retention of earnings and QIIG's accumulated surplus within the PHF. An offsetting factor to the assessment is QIIG's exposure to illiquid real estate assets and investments in associates, which accounted for 41.3% of its total investments as at year-end 2024. Despite this, the company maintains a robust level of liquidity, with its consolidated cash and deposits covering net technical provisions by 170.5% at year-end 2024, indicating that the company holds sufficient surplus capital to manage the higher investment risk appetite. AM Best assesses QIIG's operating performance as strong, evidenced by a five-year (2020-2024) weighted average return on equity of 16.6%. QIIG's combined family and general takaful portfolios have exhibited excellent underwriting performance over the medium term, with the five-year weighted average combined ratio of 73.1%. Underwriting performance of the general takaful book was affected adversely by underperformance of the medical segment in 2023 and 2024; however, the company has taken actions to remediate this portfolio. QIIG holds a niche position within its domestic insurance market, where it is a market-leading takaful player. The company has good diversification by line of business, offering a range of Sharia-compliant insurance products. In 2024, QIIG wrote GWC of QAR 551.2 million (USD 157.4 million). The business profile assessment is constrained by the company's geographical concentration and limited competitive position within the wider Qatari insurance market. This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments.
Yahoo
4 hours ago
- Yahoo
DOCS Boosts Client Retention via Workflow Integration and AI Tools
The renowned digital platform for U.S. medical professionals, Doximity, Inc.'s DOCS client engagement and retention strategy is built around deeply integrated, physician-first tools across its Marketing, Hiring and Workflow Solutions. By focusing on clinical utility and streamlining healthcare professionals' day-to-day workflows, the platform has seen high adoption — more than 620,000 unique providers used its clinical tools in the fourth quarter of fiscal 2025. This functional alignment with medical practices enhances relevance and trust, making Doximity an essential platform for providers. DOCS' Marketing Solutions deliver personalized campaigns through newsfeeds, workflow placements and peer messaging modules. Leveraging AI and machine learning, these solutions help pharmaceutical and health system clients reach narrowly defined clinician segments with relevant content. This targeted, data-driven approach consistently delivers measurable engagement, encouraging clients to expand usage across multiple brands or service lines. To reinforce retention, Doximity invests in a strong customer success team that works hands-on with clients to fine-tune campaigns, optimize content and provide ongoing analytics. Clients also have access to a self-serve portal for real-time insights. This approach has helped drive upsell opportunities and long-term client relationships. On the enterprise side, Workflow Solutions like Dialer Enterprise and AMiON have seen significant traction. These tools are now embedded into hospital operations, making transitions away from Doximity less likely. Additionally, recent enhancements such as Doximity GPT, an AI-powered, HIPAA-compliant writing assistant, add further value for clients by reducing administrative burden. This month, GoodRx Holdings, Inc. GDRX launched Community Link, enabling independent pharmacies to directly contract with it using cost-plus pricing. This shift enhances pharmacy engagement by improving pricing control and participation in GoodRx's proprietary offering, Integrated Savings Program. This program plays a key role in the company's efforts to improve pharmacy engagement and retention. Also this month, GoodRx introduced a new erectile dysfunction subscription service — offering virtual consults, transparent pricing and home delivery — streamlining consumer access and promoting recurring use through simplified, stigma-free digital care options. Veeva Systems Inc. VEEV continues to strengthen client engagement through its growing Vault CRM Suite, which unifies medical, sales, and service teams around a shared customer view. In its first-quarter fiscal 2026 results, Veeva Systems highlighted momentum in products like Veeva Link and Crossix, which deliver real-time insights and multichannel engagement metrics. By expanding commercial cloud adoption and investing in data-rich, modular platforms, Veeva Systems reinforces customer stickiness, driving higher retention among top-tier life sciences clients. These innovations support more intelligent, coordinated outreach across the customer journey. Shares of Doximity have gained 9.6% year to date against the industry's loss of 0.9%. Image Source: Zacks Investment Research DOCS' forward 12-month P/E of 39.4X is higher than the industry's average of 14.6X, but is lower than its three-year median of 48.9X. It carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for DOCS' fiscal 2026 earnings per share suggests a 3.5% improvement from fiscal 2025. Image Source: Zacks Investment Research Doximity stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report GoodRx Holdings, Inc. (GDRX) : Free Stock Analysis Report Doximity, Inc. (DOCS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Clinii Launches Clinii Connect-AI to Transform Patient Communication and Documentation in Chronic Care Programs
NEW YORK, June 11, 2025--(BUSINESS WIRE)--Clinii, a leader in AI-powered Chronic Care Management platforms, today announced the launch of Clinii Connect-AI, a fully native add-on to its core care management platform. Developed entirely in-house, Clinii Connect-AI replaces third-party tools and outdated phone systems with embedded, real-time communication and intelligent automation—all seamlessly integrated into the Clinii interface. With Clinii Connect-AI, care coordinators can manage two-way messaging, web-based voice calls, AI-generated summaries, guided call screens, sentiment tracking, and task creation—all directly from within the Clinii platform. No external software or plug-ins are required. This unified experience enhances what is already one of the industry's most comprehensive solutions for Chronic Care Management (CCM) at scale. "This is more than a communication feature—it's a purpose-built tool designed specifically for the needs of chronic care programs," said Peri Avitan, CEO of Clinii. "While many generic platforms exist, we chose to build something fundamentally different—developed 100% in-house with no third-party dependency. Clinii Connect-AI is intelligent, efficient, and fully aligned with real-world care delivery." Clinii Connect-AI addresses common inefficiencies in care coordination, including limited documentation, lack of visibility into patient sentiment, and time-consuming post-call workflows. With this add-on, every interaction becomes a traceable, billable, and actionable touchpoint—without leaving the platform. Clinii's enterprise customers have already started integrating Clinii Connect-AI into daily operations, using its real-time communication and AI-powered documentation to streamline workflows and improve billing compliance. Key Features of Clinii Connect-AI: Two-Way Messaging: SMS and in-app chat fully integrated with the patient record Embedded Voice Calling: HIPAA-compliant, web-based voice calls with in-call messaging and recording controls AI-Powered Call Guides: Guided call screens that scan care plans, clinical notes, and medications to help coordinators lead focused, compliant conversations Real-Time Summarization: Automated transcription, summaries, and structured clinical notes Sentiment Analysis: Tone detection to flag high-risk or emotionally charged conversations Task Automation: Follow-up items are extracted and converted into care team tasks A short demo video is available at: Clinii Connect-AI will be available to all customers starting Tuesday, June 17, 2025. About CliniiClinii is a digital health company transforming Chronic Care Management through AI-powered automation, workflow integration, and scalable communication. Clinii enables healthcare organizations to deliver compliant, efficient, and patient-centered care at scale. View source version on Contacts media@ |
